tiprankstipranks
Pacira reports preliminary net product sales of $57.5M for November
The Fly

Pacira reports preliminary net product sales of $57.5M for November

Pacira BioSciences reported preliminary unaudited net product sales of $57.5 million for the month of November 2022. The company’s net product sales include EXPAREL, ZILRETTA, and the iovera degrees system. The company began recognizing sales of ZILRETTA in November 2021 after completing its acquisition of Flexion Therapeutics, Inc. "As many of our large hospital customers are facing unprecedented financial challenges, we have rolled out a number of new programs to make EXPAREL more readily available to a broader range of potential new patients. Key programs include an expanded contracting strategy offering single-digit discounting to many of our large hospital customers and the implementation of 340B pricing, which opens up access to 5,200 new accounts. In addition, our collaboration with Sevredent is providing access to more than 1,800 oral and maxillofacial surgery facilities, allowing us to build a new customer base within this surgical specialty," said Dave Stack, CEO. "With expanding manufacturing capacity and improving gross margins, we have an incentive to sell every EXPAREL unit we can manufacture. These programs are a win-win that should significantly drive EXPAREL volume growth and more than offset the single-digit impact to our net selling price. We expect these programs to be accretive to net revenues in 2023 and beyond as we access a much larger customer base representing thousands of new patients. Most importantly, these programs allow more patients to benefit from EXPAREL and advances our mission to provide a non-opioid pain management solution to as many patients as possible."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on PCRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles